State Street
CCCC icon

State Street’s C4 Therapeutics CCCC Stock Holding History

State Street’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
382,973
+40,200
+12% +$94.7K ﹤0.01% 3486
2025
Q4 		$655K Buy
342,773
+55,400
+19% +$131K ﹤0.01% 3616
2025
Q3 		$638K Hold
287,373
– – ﹤0.01% 3606
2025
Q2 		$411K Sell
287,373
-937,045
-77% -$1.36M ﹤0.01% 3660
2025
Q1 		$1.96M Buy
1,224,418
+1,400
+0.1% +$4.18K ﹤0.01% 3252
2024
Q4 		$4.4M Sell
1,223,018
-1,583,895
-56% -$7.88M ﹤0.01% 3027
2024
Q3 		$16M Sell
2,806,913
-188,035
-6% -$1.13M ﹤0.01% 2341
2024
Q2 		$13.8M Sell
2,994,948
-4,158,332
-58% -$24.8M ﹤0.01% 2367
2024
Q1 		$58.4M Buy
7,153,280
+6,997,907
+4,504% +$54.2M ﹤0.01% 1642
2023
Q4 		$878K Hold
155,373
– – ﹤0.01% 3507
2023
Q3 		$289K Hold
155,373
– – ﹤0.01% 3831
2023
Q2 		$427K Sell
155,373
-618,848
-80% -$1.99M ﹤0.01% 3731
2023
Q1 		$2.43M Sell
774,221
-1,673,376
-68% -$9.85M ﹤0.01% 3278
2022
Q4 		$14.4M Buy
2,447,597
+485,785
+25% +$4.03M ﹤0.01% 2465
2022
Q3 		$17.2M Buy
1,961,812
+1,245,369
+174% +$12.9M ﹤0.01% 2332
2022
Q2 		$5.4M Sell
716,443
-1,511,316
-68% -$13.3M ﹤0.01% 3064
2022
Q1 		$54M Buy
2,227,759
+638,006
+40% +$15.5M ﹤0.01% 1709
2021
Q4 		$51.2M Sell
1,589,753
-68,877
-4% -$2.72M ﹤0.01% 1791
2021
Q3 		$74.1M Buy
1,658,630
+288,008
+21% +$12.3M ﹤0.01% 1508
2021
Q2 		$51.9M Buy
1,370,622
+507,389
+59% +$18.2M ﹤0.01% 1817
2021
Q1 		$31.9M Buy
863,233
+698,102
+423% +$27.8M ﹤0.01% 2058
2020
Q4 		$5.47M Buy
+165,131
New +$4.79M ﹤0.01% 2917

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street's CCCC Position: Q1 2026 in Review

State Street increased its C4 Therapeutics (CCCC) stake by 12% in Q1 2026, buying an estimated $94.7K and bringing the position to 382,973 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3486.

State Street first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $74.1M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • State Street held 382,973 shares of C4 Therapeutics worth $1.01M as of Q1 2026.
  • State Street bought 40,200 C4 Therapeutics shares in Q1 2026, an estimated $94.7K.
  • C4 Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3486 holding.
  • State Street first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • State Street's C4 Therapeutics position peaked at $74.1M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.